# US 2012/0252743 A1 · Trypsin-like serine protease inhibitors, their preparation and use as selective inhibitors of the clotting factors iia and xa

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252743 A1
- Document ID: US20120252743A1
- Status: Published application
- Kind: A1
- Application number: 13/332,900
- Filed: 2011-12-21
- Published: 2012-10-04
- Earliest claimed: 2010-12-21
- Assignees: The Medicines Company (Leipzig) GmbH
- Inventors: Peter Herold; Stjepan Jelakovic; Mohammed Daghish; Claudia Reichelt; Alexander Schulze; Andrea Schweinitz; Friedrich-Alexander Ludwig; Adel Rafai Far; Ting Kang
- Web page: https://patentgrep.com/patent/US20120252743A1

## CPC

- C07K 5/06121: {the second amino acid being aromatic or cycloaliphatic}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 5/06104: {with the first amino acid being acidic}
- C07K 5/06113: {Asp- or Asn-amino acid}
- C07K 5/06191: {containing heteroatoms different from O, S, or N}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides methods of making and using compounds of the formula: or a pharmaceutically acceptable salt thereof; wherein n is an integer between 1 and 2 inclusively; m is an integer between 0 and 2 inclusively; X is selected from the group consisting of CH or N; R1 is selected from the group consisting of —CH2NH2, and R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl; R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and R4 is selected from the group consisting of —OH, wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(═O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H, a simple (C1-C3) alkyl or a simple (C1-C3) acyl. These compounds are useful as anticoagulant agents as a result of their selective dual inhibition of thrombin and prothrombinase.

## Claims

### Claim 1

A compound having the following formula
or a pharmaceutically acceptable salt thereof;
wherein:
n is an integer between 1 and 2 inclusively;
m is an integer between 0 and 2 inclusively;
X is selected from the group consisting of CH or N;
R1 is selected from the group consisting of —CH2NH2, and
R2 is selected from the group consisting of —H, —OH, —NH2 and acetyl;
R3 is selected from the group consisting of —H, benzyloxycarbonyl and benzylsulfonyl; and
R4 is selected from the group consisting of —OH,
wherein p is an integer between 0 and 2 inclusively, Y is selected from the group consisting of —O—, —S—, —S(═O)—, —SO2—, methylene, —CH(OH)—, —CH(NH2)—, —CH(CH2—OH)—, —CH(CH2—NH2)— or —N(R6)—, R5 is selected from the group consisting of —H or a simple (C1-C3) alkyl and R6 is selected from the group consisting of —H; a simple (C1-C3) alkyl or a simple (C1-C3) acyl.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein R3 is selected from the group consisting of benzyloxycarbonyl and benzylsulfonyl.

### Claim 3 (depends on 1)

A compound according to claim 1, wherein R4 is

### Claim 4 (depends on 1)

A compound according to claim 1, wherein R4 is selected from the group of
wherein R5 is —H or methyl.

### Claim 5 (depends on 4)

A compound according to claim 4, wherein R4 is

### Claim 6 (depends on 1)

A compound according to claim 1, wherein n is 2.

### Claim 7 (depends on 1)

A compound according to claim 1, wherein m is 1.

### Claim 8 (depends on 1)

A compound according to claim 1, wherein X is CH, and R2 is —H or —NH2.

### Claim 9 (depends on 1)

A compound according to claim 1, wherein R1 is —CH2NH2.

### Claim 10 (depends on 1)

A compound according to claim 1, wherein R1 is —CH2NH2, n is 1 or 2 and R4 is selected from the group of
and R5 is —H or methyl.

### Claim 11 (depends on 1)

The compound of claim 1, selected from the group of
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising one or more compounds according to claim 1, further comprising one or more pharmaceutically acceptable carriers or excipients.

### Claim 13 (depends on 1)

A method for the treatment of a condition where anticoagulation is indicated, comprising administering to a patient in need thereof an effective amount of one or more compounds according to claim 1.

### Claim 14 (depends on 1)

A method for the therapy or prevention of a cardiovascular disorder, a thrombotic disease condition or a thromboembolic event in a patient, comprising administering to said patient an effective amount of one or more compounds according to claim 1.

### Claim 15 (depends on 1)

A method to establish reperfusion or to delay reocclusion of the blood circulation in a patient, comprising administering to said patient an effective amount of one or more compounds according to claim 1.

### Claim 16 (depends on 1)

A method for selectively dually inhibiting human thrombin and Factor Xa in a patient, comprising administering to said patient an effective amount of one or more compounds according to claim 1.

### Claim 17 (depends on 1)

A method of selectively dually inhibiting thrombin and Factor Xa in a patient or in extracorporeal blood comprising the step of treating said patient or said extracorporeal blood with one or more compounds according to claim 1.

### Claim 18 (depends on 17)

The method according to claim 17, wherein said method is used for
treating or preventing a cardiovascular disorder or of a thromboembolic event in a patient; or
treating or preventing thrombin-induced inflammation in a patient; or
to inhibit thrombus accretion in a patient caused by clot-bound thrombin; or
inhibiting platelet-dependent thrombosis in a patient; or
treating or preventing disseminated intravascular coagulation in a patient.

### Claim 19 (depends on 18)

The method according to claim 18, wherein said inflammation is caused by a disease selected from the group consisting of adult respiratory distress syndrome, septic shock, septicemia and reperfusion damage.
